Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Type 2 Diabetes Mellitus (T2DM)Continuous Glucose MonitoringCGMTransition to DischargeSmart Insulin Pen Cap
Interventions
DEVICE

Usual Care group

Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.

DEVICE

Technological group

Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.

Trial Locations (1)

46026

RECRUITING

Hospital La Fe, Valencia, Valencia

All Listed Sponsors
lead

Instituto de Investigacion Sanitaria La Fe

OTHER